News - 14 Sep `20AVITA Medical: clinical trials in the USA

New

First patient enrolled in AVITA Therapeutic’s study in Miami earlier this week. The prospective study is evaluating the RECELL system for repigmentation of patients with stable vitiligo, meaning they have not had new vitiligo lesions or lesions that have expanded for at least one year.

AVITA’s technology creates an autologous suspension from a piece of the patient's own normal skin in under 30 minutes, to spray pigment-producing cells onto vitiligo lesion.

The company is about to begin two multi-center clinical trials in the USA (details 1 and details 2)

For more information, please contact: Elizabeth Kirshner at 661-367-9180 or ekirshner@avitamedical.com

 



      FAQOther Questions

      • Which diseases most commonly accompany vitiligo?

        Vitiligo is an autoimmune disease and is frequently associated with other autoimmune diseases, acccording to a 10-year study. The exact diseases that accompany vitiligo can vary...

      • Will it spread?

        Vitiligo's progression and response to treatment can vary significantly among individuals, making it a particularly unpredictable skin condition. Based on the VALIANT study, her...

      • Are there any famous people with vitiligo?

        Many celebrities have dealt with vitiligo while remaining in the public eye, maintaining a positive outlook, and having a successful career. Here are a few courageous famous peo...